In the present study, DNA oxidative damage was elevated and superoxide dismutase (Cu,Zn-SOD) metabolism was disturbed in the kidney of alloxan-induced diabetic animals. The effects of pioglitazone and repaglinide, new oral antidiabetics, on 8-hydroxy-2'-deoxyguanosine (8-OHdG) and Cu,Zn-SOD were studied. Diabetic versus control levels (mean ± SE) of 8-OHdG were 24.9 ± 0.2 vs. 21.8 ± 0.1 and 21.5 ± 0.2 vs 20.1 ± 0.2 pmol/µg DNA after 4 and 8 weeks, respectively. At p<0.05, pioglitazone diminished this parameter in diabetic animals (22.0 ± 0.2 and 20.1 ± 0.3 pmol/µg DNA). The level was not affected in diabetic groups receiving repaglinide (24.9 ± 0.2 and 21.5 ± 0.3 pmol/µg DNA). In diabetic kidney, Cu,Zn-SOD mRNA was diminished relative to control animals and was modulated by pioglitazone and repaglinide treatments. Simultaneously, Cu,Zn-SOD activity was also diminished (1.5 ± 0.2 vs. 2.8 ± 0.3 and 1.8 ± 0.1 vs 2.9 ± 0.3 U/mg protein after 4 and 8 weeks, respectively) and partly changed after pioglitazone (2.1 ± 0.4 and 2.3 ± 0.3 U/mg protein) and repaglinide (2.0 ± 0.1 and 2.4 ± 0.2 U/mg protein). These results suggest that a reduction in oxidative stress in diabetic kidney can be achieved with the administration of pioglitazone and to some extent using repaglinide treatment.
Introduction
Reactive oxygen species can react with various biological targets including DNA and may be an important factor in the development of diabetic complications [1] . Among all purine and pyridine bases, guanine is most prone to oxidation via the hydroxylation of its 8 th position. This modified product, 8-hydroxy-2'-deoxyguanosine , gives rise to one of the predominant forms of oxidative DNA damage [2] . So far, increases in the level of 8-OHdG have been reported in mononuclear cells or leukocytes from patients with type 1 and type 2 diabetes mellitus [3, 4] and in different tissues from diabetic animals [1, [5] [6] [7] . High levels of urinary 8-OHdG have also been reported in diabetic patients and animals [2, 8, 9] . Therefore, the first aim of the present study was to investigate whether hyperglycemia could induce DNA oxidative damage in the kidney of diabetic rabbits.
It is known that hyperglycemia can influence the expression and activity of important antioxidative enzymes, including superoxide dismutase [10] [11] [12] [13] [14] [15] [16] [17] . In one previous experiment, the ability of renal cells to respond to glucose-induced oxidative stress by increasing levels of SOD mRNA was confirmed [11] . Therefore, the second aim of the present study was to investigate whether hyperglycemia could change the expression and activity of Cu,Zn-SOD in the kidney of diabetic rabbits.
Pioglitazone and repaglinide are new oral antidiabetic drugs that are often used in therapy of type 2 diabetes mellitus [18] . Pioglitazone, an agonist of nuclear peroxisome proliferator-activated receptor γ (PPARγ), was shown to affect some parameters of oxidative stress [19] [20] [21] [22] . Some positive effects were also observed after addition of repaglinide, a short acting blocker of beta cell K AT P channels [23] [24] [25] . Hence, the final aim of the present study was to examine whether these two different oral antidiabetics could affect the oxidative DNA damage and Cu,Zn-SOD metabolism in the kidney of diabetic animals.
Because oxidative stress is enhanced by chronic hyperglycemia, the action of pioglitazone or repaglinide on glucose levels may indirectly affect the parameters of oxidative stress. We were interested in distinguishing potential antioxidative effects of the drugs from their action on insulin sensitivity or insulin secretion. So, we decided to use the alloxan-induced (insulin deficient) diabetic animals, in which pioglitazone could not intensify insulin sensitivity and repaglinide could not stimulate insulin secretion.
To our knowledge, the action of pioglitazone and repaglinide on DNA oxidative damage in diabetes has not been examined so far. It is also the first report concerning the action of pioglitazone and repaglinide on Cu,Zn-SOD expression, based on in vivo experiments.
Experimental and clinical studies suggest that oxidative stress appears in type 1 as well as in type 2 diabetic patients [26, 27] . If pioglitazone and repaglinide show direct antioxidative action in alloxan-induced diabetic animals, similar effects of the drugs should appear in type 2 diabetic patients, contributing to more effective therapy.
Materials and methods

Animals
The study was performed in male New Zealand rabbits with a mean body mass of 3.1 kg, according to the Guidelines of Animal Ethics Committee of Medical University of Lublin. Diabetes was induced by a single intravenous injection of alloxan (80 mg/kg). Two weeks after the alloxan injection, the animals were divided into six groups of 10 rabbits: normal control (group CO), normal receiving pioglitazone (1 mg/kg, group CP), normal receiving repaglinide (0.3 mg/kg, group CR), control diabetic (group DO), diabetic receiving pioglitazone (1 mg/kg, group DP) and diabetic receiving repaglinide (0.3 mg/kg, group DR). The drugs were administered once daily before the morning feeding. After 4 and 8 weeks, the rabbits were sacrificed by a single intravenous injection of pentobarbital sodium (60 mg/kg). The kidneys from control and diabetic animals were immediately removed, washed with ice-cold sterile saline, dried, frozen in liquid nitrogen and stored at -70
• C until analysis. 
Chemicals and reagents
Biochemical measurements
Blood glucose concentrations were estimated with a glucometer Precision QID from Abbott UK Limited (UK). Plasma insulin concentrations were determined using an Ul- 2.4 DNA extraction DNA was extracted from the kidney tissue, using a standard procedure of Hirt [28] . Samples of 150 mg were homogenized in 1 ml of the buffer consisting of 10 mM Tris, 10 mM EDTA and 1% SDS. After centrifugation, the supernatant was incubated with 25 μl of proteinase K (100 μg/ml) at 37
• C for 12 h. Then, extraction with saturated phenol, chloroform and isoamyl alcohol was performed, followed by centrifugation at 3000 rpm for 15 min. DNA samples were precipitated with 7.5 M ammonium acetate and absolute ethanol at -20
• C for 12 h, and centrifuged at 14000 rpm for 30 min. Then they were dried, resuspended in 45 μl of sodium acetate (20 mM, pH 4.8) and digested to nucleotides by incubation with 5 μg of nuclease P1 at 37
• C for 30 min. This was followed by the addition of 5 μl Tris (1 M, pH 7.4) and 0.5 U of E. coli alkaline phosphatase, and incubation at 37
In situ hybridization
The specimens were fixed in neutral buffered formaldehyde, dehydrated in increasing concentrations of ethanol and embedded in paraffin. Sections of 5 μm thickness were cut on a microtome, transferred onto microscopic slides and heated at 50
• C for 30 min.
Before hybridization, paraffin was removed from sections with xylene, and the sections were then rehydrated by rinsing with successive dilutions of ethanol. 100 μl of proteinase K (100 μg/ml) was then applied to each section and the slides were incubated at room temperature for 30 min. Sections were rinsed with PBS, denaturated at 90 
Cu,Zn-SOD extraction
The kidney homogenates (20% in phosphate buffer at pH 7.5) were mixed with an icecold extraction reagent containing absolute ethanol and chloroform (62.5:37.5, v/v) and centrifuged at 4000 rpm for 5 min at 4
• C. The upper layers were collected for further analysis. During this procedure, Mn-SOD and Fe-SOD were shown to be inactivated. Therefore, the supernatants were suitable for the accurate determination of Cu,Zn-SOD activity.
Statistical analysis
Analysis of numerical data was performed by ANOVA, followed by Scheffe's post-hoc test when variances were equal. Non parametric data were subjected to Kruskal-Wallis and U Mann-Whitney tests. Differences were considered significant when p<0.05. For statistical evaluation, Statistica software (version 5.0) was used.
Results
Glucose and insulin concentrations
A consistent hyperglycemic state was observed in diabetic rabbits after both 4 and 8 weeks. In diabetic animals, insulin levels were lower than control groups at both stages of the experiment. Pioglitazone did not affect glucose and insulin concentrations in both the control and diabetic animals. Repaglinide did not affect the glucose concentrations in diabetic animals. This concentration was decreased in control rabbits receiving the drug for 4 weeks but after 8 weeks, the glucose levels were similar to that in the control group. Repaglinide did not affect insulin concentrations in diabetic animals. Insulin levels were increased in control rabbits receiving the drug during 4 weeks but after 8 weeks, the change was not significant (Table 1) .
DNA damage
Some differences in the level of 8-OHdG were noticeable between the 4 and 8 week groups., These differences were probably caused by the use of two different batches of ELISA kits and solvents in the extraction procedure. For this reason, we did not compare the results obtained for these two periods. In the kidney of diabetic animals, DNA oxidation Table 1 Changes in blood glucose, plasma insulin, renal 8-hydroxy-2'-deoxyguanosine (8-OHdG) and renal superoxide dismutase (Cu,Zn-SOD) in control and diabetic animals (mean ± SE, n=5).
was significantly higher than in control groups after both experimental periods. This parameter was not affected in control animals receiving pioglitazone. In diabetic groups, pioglitazone diminished the level of 8-OHdG as compared to diabetic non-treated groups after 4 and 8 weeks. The level of oxidative damage was not affected in control animals receiving repaglinide. Differently to pioglitazone, repaglinide did not affect this parameter in diabetic animals ( Table 1 ).
Cu,Zn-SOD expression
Significant differences in staining intensity were obtained between our experimental groups after both experimental periods. Finally, the changes observed after 8 weeks of experiment were documented and discussed. Using the forward (antisense) primer, tissue sections showed positive fluorescent signals (bright green fluorescence). In diabetic group (Fig. 1B) , some positive signals were seen, in less than 50% positive signals as compared to control healthy animals (Fig. 1A) . In the kidney of control animals receiving pioglitazone (Fig. 1C) or repaglinide (Fig. 1E) , the expression of Cu,Zn-SOD remained rather stable after the treatment. With respect to cellular localization and relative staining intensity, the patterns were similar to those observed in control healthy group. These sections showed greater than 90 % positive signals. In diabetic tissue, pioglitazone treatment brought the expression level close to that seen in the control rabbits. In this group, a strong cytoplasmatic reaction was observed with nearly normal mRNA distribution, and more than 90% positive signals were observed (Fig. 1D) . A trend toward increasing the amounts of mRNA was observed in diabetic repaglinide treated animals. However, in this group the staining was localized less homogeneously than in the case of pioglitazone, in around 60-80% positive signals as compared to control animals (Fig. 1F). 
Cu,Zn-SOD activity
In the kidney of diabetic animals, the enzyme activity was significantly lower than in the control groups, after both experimental periods. This parameter was not affected in control animals receiving pioglitazone. In diabetic groups, pioglitazone increased Cu,Zn-SOD activity but the changes were not significant as compared to diabetic non-treated animals. This parameter was not affected in control groups receiving repaglinide. In diabetic groups, repaglinide increased Cu,Zn-SOD activity but the changes were significant solely after 8 weeks (Table 1 ).
Discussion
Some previous studies have reported the increased expression of several antioxidant enzymes in diabetic kidney, suggesting a compensatory response to increased free radical production [5, 7, 11, 13] . In addition, some authors have described significant hyperglycemia-induced increases in SOD activity [15] [16] [17] . However, the results have differed and some controversy still exists [8, 12, 14] . In the present study, this compensatory induction was hindered, probably as a result of rapid and severe hyperglycemia. Similar effects were observed in the kidney of streptozotocin-induced diabetic mice [8] and alloxan-induced diabetic rats [14] .
In the present study, we demonstrated that the expression of Cu,Zn-SOD in diabetic kidney was modulated by pioglitazone treatment. In the literature, high levels of Cu,Zn-SOD expression (in response to pioglitazone) were reported in the cultured human endothelial cells [21] . This and the present findings demonstrate that pioglitazone can induce favorable changes in the expression of antioxidant enzymes, including Cu,Zn-SOD. However, the changes of the enzyme activity in the present study were less significant, probably due to some post-transcriptional modifications.
Repaglinide operates via a mechanism similar to that of sulfonylureas, some of which have been reported to possess antioxidative properties. However, the action of repaglinide and sulfonylureas on Cu,Zn-SOD expression has been examined poorly so far. In one previous study, Cu,Zn-SOD mRNA was elevated by gliclazide in pancreatic beta cells treated with H 2 O 2 [30] .
Our results suggest that repaglinide can elevate Cu,Zn-SOD mRNA in diabetic kidneys. At the same time, the enzyme activity was partly elevated. In the literature, an increase in the enzyme activity after repaglinide was observed in the serum of type 2 diabetic patients [25] . SOD activity was also normalized by gliclazide in the red blood cells of diabetic patients [31] and by glyburide in tissues of diabetic animals [32] . However, in type 2 diabetes, this normalization could be partly attributed to the drugs dependent improvement in glycemic control. Fig. 1 Hybridization on paraffin embedded kidney sections from control (A, C, E) and diabetic (B, D, F) rabbits after 8 weeks of experiment. Using the antisense probes, Cu,Zn-SOD mRNA showed a bright green fluorescence. Diabetic animals (B; hybridization score +) showed diminished mRNA levels as compared to control group (A; 100 % positive signals). In the kidney of control animals receiving pioglitazone (C; hybridization score +++) and repaglinide (E; hybridization score +++), the expression remained stable after the treatments. In diabetic kidney, pioglitazone brought the expression level close to that seen in control rabbits (D; hybridization score +++). A trend toward increasing amounts of mRNA was observed in diabetic repaglinide-treated animals (F; hybridization score ++). Tissue sections were photographed at × 500. Scale bar=70 μm.
So far, significant increases of 8-OHdG level have been observed in the kidney of streptozotocin-induced diabetic rats [6, 7] . This is in agreement with the present results concerning the alloxan-induced diabetic rabbits. This DNA oxidative damage might arise from an overwhelmed antioxidant defense. Some previous results have showed that wellknown antioxidants, ascorbic acid, trolox, probucol and α-tocopherol, might reduce DNA damage in tissues of diabetic animals [6] . The protective effects of these antioxidants might be due to the scavenging of free radicals or the prevention of oxidative processes. In the present study, the level of 8-OHdG in diabetic kidney was decreased after pioglitazone treatment. This might be due to the scavenging of reactive oxygen species by the drug and, to even greater extent, by its metabolites. Hydroxylation of phenyl and pyridine rings in the structure of pioglitazone might intensify the antioxidative action of the drug and facilitate scavenging of hydroxyl radicals [33] . On the other hand, it was shown that oxidative stress in diabetes caused DNA damage together with modulation of the activity of some redox-sensitive transcription factors, including nuclear factor κB (NF-κB) [1] . It is also known that some PPARγ agonists have a suppressive effect on NF-κB activation [34] . Therefore, it is probably that pioglitazone, a PPARγ agonist, exerts its antioxidative properties by antagonizing the activity of NF-κB. However, the complete elucidation of the antioxidant mechanism of this drug requires further evaluation.
In contrast to pioglitazone, our study suggests that repaglinide had a smaller effect on DNA oxidation, even though it improved the Cu,Zn-SOD metabolism to a similar extent. The reason for this might be related to different mechanisms of antioxidative action of both the drugs, e.g. different ability to scavenge hydroxyl radicals. It is known that DNA can be damaged in many ways by different reactive oxygen species [6] . However, 8-OHdG is formed mainly by the attack of hydroxyl radicals [35] . On the other hand, repaglinide is a highly lipophilic benzoic acid derivative. In the literature concerning similar compounds, there is some information about their activity towards the hydroxyl radical [36] . However, our results did not confirm such activity of repaglinide in relation to 8-OHdG in diabetic kidney. The difference between repaglinide and pioglitazone was also observed in relation to protein oxidation in plasma of our diabetic animals [22, 23] .
The results presented herein suggest that Cu,Zn-SOD metabolism is disturbed in the kidney of diabetic animals. Cu,Zn-SOD mRNA was diminished relative to control animals and modulated by pioglitazone and repaglinide. Simultaneously, Cu,Zn-SOD activity was also diminished and partly changed after the treatment. The elevation of DNA oxidative damage, expressed as the level of 8-OHdG, was also observed. Pioglitazone diminished this parameter in diabetic animals. However, the level of 8-OHdG was not affected in diabetic groups receiving repaglinide. Our results suggest that pioglitazone shows greater antioxidative impact in this experimental model.
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